|5.28||-0.1800||-3.30%||Vol 551||1Y Perf -8.65%|
|Sep 22nd, 2020 14:50 DELAYED|
|- -%||- -%|
|Target Price||14.00||Analyst Rating||— — 0.00|
|Potential %||165.15||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★★★+ 55.93|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||★★★★ 58.22|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Market Cap||38.08M||Earnings Rating||Neutral|
|Price Range Ratio 52W %||35.67||Earnings Date||9th Nov 2020|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Nov 2020|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||5.80K|
|Avg. Monthly Volume||8.48K|
|Avg. Quarterly Volume||16.91K|
ImmuCell Corporation (NASDAQ: ICCC) stock closed at 5.28 per share at the end of the most recent trading day (a -3.3% change compared to the prior day closing price) with a volume of 551.0000 shares and market capitalization of 38.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 52 people. ImmuCell Corporation CEO is Micheal F. Brigham.
The one-year performance of ImmuCell Corporation stock is -8.65%, while year-to-date (YTD) performance is 2.52%. ICCC stock has a five-year performance of -14.42%. Its 52-week range is between 3.7 and 8.13, which gives ICCC stock a 52-week price range ratio of 35.67%
ImmuCell Corporation currently has a PE ratio of -, a price-to-book (PB) ratio of 1.44, a price-to-sale (PS) ratio of 2.72, a price to cashflow ratio of 23.80, a PEG ratio of 2.32, a ROA of -4.25%, a ROC of -2.98% and a ROE of -5.87%. The company’s profit margin is -11.75%, its EBITDA margin is 8.20%, and its revenue ttm is $14.48 Million , which makes it $2.01 revenue per share.
Of the last four earnings reports from ImmuCell Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. ImmuCell Corporation’s next earnings report date is 09th Nov 2020.
The consensus rating of Wall Street analysts for ImmuCell Corporation is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ImmuCell Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ImmuCell Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ImmuCell Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.63, ATR14 : 0.25, CCI20 : -19.72, Chaikin Money Flow : -0.07, MACD : -0.03, Money Flow Index : 64.93, ROC : -0.75, RSI : 47.14, STOCH (14,3) : 31.48, STOCH RSI : 0.13, UO : 42.00, Williams %R : -68.52), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ImmuCell Corporation in the last 12-months were: David S. Cunningham (Buy at a value of $8 000), David S. Tomsche (Buy at a value of $45 235)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.